clinical-lymphoma-myeloma-leukemia

References in Tolerance, kinetics and depth of response for ...

Subcutaneous bortezomib in multiple myeloma patients induces similar therapeutic response rates as intravenous application but it does not reduce the incidence of peripheral neuropathy. PLoS One. 2015;10:e0123866.. Google Scholar. 15Ong, S.Y., Ng, H.Y., Surendran, S. et al, Subcutaneous bortezomib combined with ...